China Pharmahub Acquires Humanized Antibody Technology To Target China's Nascent Market
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI- In-licensing firm China PharmaHub recently announced it is stepping into the antibody space with a joint venture targeted to bring novel humanized antibody technology to China
You may also be interested in...
China's Big Cities Should Be First Priority For Pharma Companies - IMS
SHANGHAI- China's largest cities control the majority of the Chinese pharma market, and companies must decide city-specific sales strategies, according to the global healthcare data provider and consulting firm IMS Health
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).